Vaxart CEO and Founder to Discuss Moving the Needle: Blocking Transmission and Boosting Existing Vaccines through Oral Tablet Vaccination at World Vaccine Congress Washington 2024

Vaxart, Inc. located in South San Francisco, California announced that Dr. Sean Tucker, the company’s Founder and Chief Scientific Officer, will be presenting at the World Vaccine Congress Washington 2024 in Washington, D.C on April 3, 2024. This presentation is a recurring appearance for the company at the annual event in Washington, D.C.

During the presentation, Dr. Tucker will discuss “Moving the needle: Blocking transmission and boosting existing vaccines by oral tablet vaccination.” The presentation is scheduled for Wednesday, April 3, 2024 at 3:10 p.m Eastern Time in Room 207A.

Vaxart is a clinical-stage biotechnology company focused on developing oral recombinant vaccines using its proprietary delivery platform. These vaccines are designed to be administered via pills, allowing for easy storage and shipping without refrigeration while eliminating the risk of needle-stick injuries. The company believes that its pill vaccine delivery platform is well-suited for delivering a range of vaccines, including oral versions of existing vaccines and new indications.

Currently, Vaxart’s development programs include pill vaccines for protection against coronavirus, norovirus and influenza as well as a therapeutic vaccine for human papillomavirus (HPV), the company’s first immune-oncology indication. Vaxart has also filed various patent applications domestically and internationally to cover its proprietary technology and creations related to oral vaccination using adenovirus and TLR3 agonists.

For media relations inquiries please contact Mark Herr at Vaxart Inc., For investor relations inquiries reach out to Andrew Blazier